Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Nasopharyngeal Carcinoma 4 Triple Negative Breast Neoplasms 3 Esophageal Squamous Cell Carcinoma 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Salivary Gland Neoplasms 1 Rectal Cancer Patients 1 Pancreatic Neoplasms 1 Locally Advanced Rectal Cancer 1 Esophageal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Fulvestrant 64 Paclitaxel 55 Letrozole 54 Trastuzumab 43 pembrolizumab 41 ribociclib 39 Capecitabine 36 palbociclib 35 Specimen Handling 34 Carboplatin 34 Anastrozole 34 exemestane 31 abemaciclib 31 Tamoxifen 31 pertuzumab 29 Cyclophosphamide 27 Magnetic Resonance Spectroscopy 25 trastuzumab deruxtecan 24 Surveys and Questionnaires 21 Radiotherapy 21 Blood Specimen Collection 21 olaparib 18 Standard of Care 17 Docetaxel 17 Biopsy 17 130-nm albumin-bound paclitaxel 16 eribulin 14 Taxes 14 Methods 14 Mastectomy, Segmental 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × camrelizumab × 90 days × Clear all

NCT05582499 2026-05-28

FASCINATE-N

Fudan University

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡